You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 18, 2024

Details for New Drug Application (NDA): 012380

✉ Email this page to a colleague

« Back to Dashboard

NDA 012380 describes ZARONTIN, which is a drug marketed by Parke Davis and Parke-davis and is included in two NDAs. It is available from two suppliers. Additional details are available on the ZARONTIN profile page.

The generic ingredient in ZARONTIN is ethosuximide. There is one drug master file entry for this compound. Nine suppliers are listed for this compound. Additional details are available on the ethosuximide profile page.
Summary for 012380
Applicant:Parke Davis
Formulation / Manufacturing:see details
Pharmacology for NDA: 012380
Medical Subject Heading (MeSH) Categories for 012380
Suppliers and Packaging for NDA: 012380
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZARONTIN ethosuximide CAPSULE;ORAL 012380 NDA Parke-Davis Div of Pfizer Inc 0071-0237 0071-0237-24 100 CAPSULE in 1 BOTTLE (0071-0237-24)
ZARONTIN ethosuximide CAPSULE;ORAL 012380 NDA AUTHORIZED GENERIC Greenstone LLC 59762-2250 59762-2250-2 100 CAPSULE in 1 BOTTLE (59762-2250-2)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength250MG
Approval Date:Approved Prior to Jan 1, 1982TE:ABRLD:Yes

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.